# Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

> **NCT00322218** · PHASE3 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 68 (actual)

## Conditions studied

- Lymphoma, Large Cell, Diffuse

## Interventions

- **DRUG:** Zevalin

## Key facts

- **NCT ID:** NCT00322218
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** due to low recruitment rate that would have led to a long study duration.
- **Last updated:** 2022-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322218, "Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00322218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*